- Home
- SXC vs KROS Comparison
SXC vs KROS Comparison
Compare SXC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SXC | KROS |
|---|---|---|
| Founded | 1960 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 549.5M | 655.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SXC | KROS |
|---|---|---|
| Price | $7.21 | $20.04 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | $10.00 | ★ $22.20 |
| AVG Volume (30 Days) | ★ 1.3M | 971.2K |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.75 | ★ 1.57 |
| Revenue | ★ $1,843,100,000.00 | $246,718,000.00 |
| Revenue This Year | N/A | $6,876.34 |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | ★ $9.56 | $12.78 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $6.24 | $9.12 |
| 52 Week High | $11.81 | $22.55 |
Technical Indicators
Market Signals| Indicator | SXC | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 55.93 | 57.46 |
| Support Level | $6.92 | $20.73 |
| Resistance Level | $7.38 | $21.75 |
| Average True Range (ATR) | 0.22 | 1.06 |
| MACD | 0.08 | -0.12 |
| Stochastic Oscillator | 75.13 | 58.36 |
Price Performance
Historical ComparisonAbout SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.